{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:54:16Z","timestamp":1792068856383,"version":"4.4.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T00:00:00Z","timestamp":1686096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T00:00:00Z","timestamp":1686096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gastric Cancer"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>In trials evaluating perioperative chemotherapy for gastric cancer, which serve as the basis for treatment guidelines, patients are selected. The generalizability of these trial findings to older patients is uncertain.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This population-based retrospective cohort study compared the survival outcomes of patients\u2009\u2265\u200975\u00a0years with gastric adenocarcinoma treated with or without neoadjuvant chemotherapy between 2015 and 2019. Additionally, the percentage of patients\u2009&lt;\u200975\u00a0years and\u2009\u2265\u200975\u00a0years who did not proceeded to surgery after receiving neoadjuvant chemotherapy were examined.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 1995 patients, of whom 1249 aged\u2009&lt;\u200975\u00a0years and 746 aged\u2009\u2265\u200975\u00a0years, were included. In the group of patients\u2009\u2265\u200975\u00a0years, 275 patients received neoadjuvant chemotherapy and 471 patients were directly scheduled for gastrectomy. Patients\u2009\u2265\u200975\u00a0years treated with or without neoadjuvant chemotherapy differed significantly from one and another in characteristics. Overall survival of patients\u2009\u2265\u200975\u00a0years treated with or without neoadjuvant chemotherapy was not significantly different (median 34.9 vs. 32.3\u00a0months; <jats:italic>P<\/jats:italic>\u2009=\u20090.506), also after adjusting for potential confounders (HR 0.87; <jats:italic>P<\/jats:italic>\u2009=\u20090.263). Of patients\u2009\u2265\u200975\u00a0years who received neoadjuvant chemotherapy, 43 (15.6%) did not proceed to surgery compared to 111 (8.9%) patients\u2009&lt;\u200975\u00a0years (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Patients\u2009\u2265\u200975\u00a0years treated with or without chemotherapy were highly selected, and overall survival was not significantly different between both groups. Nonetheless, the proportion of patients who did not proceed to surgery following neoadjuvant chemotherapy was higher in patients\u2009\u2265\u200975\u00a0years compared to patients\u2009&lt;\u200975\u00a0years. Therefore, neoadjuvant chemotherapy should be considered with more caution in patients\u2009\u2265\u200975\u00a0years, while identifying those who may benefit.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10120-023-01404-2","type":"journal-article","created":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T08:02:41Z","timestamp":1686124961000},"page":"763-774","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Neoadjuvant chemotherapy in older patients with gastric cancer undergoing surgery: a population-based cohort study"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4027-8715","authenticated-orcid":false,"given":"Kammy","family":"Keywani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander B. J.","family":"Borgstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wietse J.","family":"Eshuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke","family":"Pape","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathelijn S.","family":"Versteeg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Derks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanneke W. M.","family":"van Laarhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne S.","family":"Gisbertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob H. A.","family":"Verhoeven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark I.","family":"van Berge Henegouwen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,7]]},"reference":[{"key":"1404_CR1","unstructured":"Kanker NL. Overlevingscijfers van maagkanker. Accessed December 17, 2022. https:\/\/kanker.nl\/kankersoorten\/maagkanker\/algemeen\/overlevingscijfers-van-maagkanker."},{"key":"1404_CR2","doi-asserted-by":"publisher","first-page":"4484","DOI":"10.1245\/s10434-020-09510-6","volume":"28","author":"DM Voeten","year":"2021","unstructured":"Voeten DM, van der Werf LR, Wilschut JA, Busweiler LAD, van Sandick JW, van Hillegersberg R, et al. Failure to cure in patients undergoing surgery for gastric cancer: a nationwide cohort study. Ann Surg Oncol. 2021;28:4484\u201396.","journal-title":"Ann Surg Oncol"},{"key":"1404_CR3","unstructured":"Federatie Medisch Specialisten. Dutch Clinical Practice Guidelines for Gastric Cancer. Accessed December 12 October, 2022. https:\/\/richtlijnendatabase.nl\/richtlijn\/maagcarcinoom."},{"key":"1404_CR4","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","volume":"33","author":"F Lordick","year":"2022","unstructured":"Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, et al. Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:1005\u201320.","journal-title":"Ann Oncol"},{"key":"1404_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa055531","volume":"355","author":"D Cunningham","year":"2006","unstructured":"Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11\u201320.","journal-title":"N Engl J Med"},{"key":"1404_CR6","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"SE Al-Batran","year":"2019","unstructured":"Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial. Lancet. 2019;393:1948\u201357.","journal-title":"Lancet"},{"key":"1404_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmjopen-2012-000833","volume":"2","author":"BA Golomb","year":"2012","unstructured":"Golomb BA, Chan VT, Evans MA, Koperski S, White HL, Criqui MH. The older the better: are elderly study participants more non-representative? A cross-sectional analysis of clinical trial and observational study samples. BMJ Open. 2012;2:1.","journal-title":"BMJ Open"},{"key":"1404_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0174053","volume":"12","author":"FJ van Deudekom","year":"2017","unstructured":"van Deudekom FJ, Postmus I, van der Ham DJ, Pothof AB, Broekhuizen K, Blauw GJ, et al. External validity of randomized controlled trials in older adults, a systematic review. PLoS ONE. 2017;12:1.","journal-title":"PLoS ONE"},{"key":"1404_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ageing\/afab282","volume":"51","author":"KH Pitkala","year":"2022","unstructured":"Pitkala KH, Strandberg TE. Clinical trials in older people. Age Ageing. 2022;51:1.","journal-title":"Age Ageing"},{"key":"1404_CR10","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1245\/s10434-012-2663-1","volume":"20","author":"YR van Gestel","year":"2013","unstructured":"van Gestel YR, Lemmens VE, de Hingh IH, Steevens J, Rutten HJ, Nieuwenhuijzen GA, et al. Influence of comorbidity and age on 1-, 2-, and 3-month postoperative mortality rates in gastrointestinal cancer patients. Ann Surg Oncol. 2013;20:371\u201380.","journal-title":"Ann Surg Oncol"},{"key":"1404_CR11","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1016\/j.ejca.2015.07.002","volume":"51","author":"L Sylvie","year":"2015","unstructured":"Sylvie L, Silvia S, Salah-Eddin AB, Markus F, Florian L, Peter TP, et al. Impact of age on the feasibility and efficacy of neoadjuvant chemotherapy in patients with locally advanced oesophagogastric cancer. Eur J Cancer. 2015;51:1918\u201326.","journal-title":"Eur J Cancer"},{"key":"1404_CR12","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1016\/j.ejso.2019.03.040","volume":"45","author":"M van Putten","year":"2019","unstructured":"van Putten M, Lemmens V, van Laarhoven HWM, Pruijt HFM, Nieuwenhuijzen GAP, Verhoeven RHA. Poor compliance with perioperative chemotherapy for resectable gastric cancer and its impact on survival. Eur J Surg Oncol. 2019;45:1926\u201333.","journal-title":"Eur J Surg Oncol"},{"key":"1404_CR13","unstructured":"Netherlands Cancer registery. Accessed October 31, 2021. Netherlands Cancer registery. Accessed October 31, 2021. https:\/\/iknl.nl\/nkr."},{"key":"1404_CR14","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.ejso.2021.08.003","volume":"48","author":"ABJ Borgstein","year":"2021","unstructured":"Borgstein ABJ, Keywani K, Eshuis WJ, van Berge Henegouwen MI, Gisbertz SS. Staging laparoscopy in patients with advanced gastric cancer: a single center cohort study. Eur J Surg Oncol. 2021;48:362\u20139.","journal-title":"Eur J Surg Oncol"},{"key":"1404_CR15","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1245\/s10434-010-0985-4","volume":"17","author":"SB Edge","year":"2010","unstructured":"Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471\u20134.","journal-title":"Ann Surg Oncol"},{"key":"1404_CR16","unstructured":"Brierley JD GMK. UICC. TNM classification of malignant tumours, 8th edition. Union Int Cancer Control. 2016."},{"key":"1404_CR17","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.1200\/JCO.2005.00.141","volume":"23","author":"CA Townsley","year":"2005","unstructured":"Townsley CA, Selby R, Siu LL. Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol. 2005;23:3112\u201324.","journal-title":"J Clin Oncol"},{"key":"1404_CR18","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/bjc.2012.588","volume":"108","author":"S Lorenzen","year":"2013","unstructured":"Lorenzen S, Pauligk C, Homann N, Schmalenberg H, J\u00e4ger E, Al-Batran SE. Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophagogastric cancer. Br J Cancer. 2013;108:519\u201326.","journal-title":"Br J Cancer"},{"key":"1404_CR19","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1002\/bjs.10802","volume":"105","author":"M Navidi","year":"2018","unstructured":"Navidi M, Phillips AW, Griffin SM, Duffield KE, Greystoke A, Sumpter K, et al. Cardiopulmonary fitness before and after neoadjuvant chemotherapy in patients with oesophagogastric cancer. Br J Surg. 2018;105:900\u20136.","journal-title":"Br J Surg"},{"key":"1404_CR20","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1308\/rcsann.2016.0135","volume":"98","author":"R Sinclair","year":"2016","unstructured":"Sinclair R, Navidi M, Griffin SM, Sumpter K. The impact of neoadjuvant chemotherapy on cardiopulmonary physical fitness in gastro-oesophageal adenocarcinoma. Ann R Coll Surg Engl. 2016;98:396\u2013400.","journal-title":"Ann R Coll Surg Engl"},{"key":"1404_CR21","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/j.ejso.2014.03.010","volume":"40","author":"S Jack","year":"2014","unstructured":"Jack S, West MA, Raw D, Marwood S, Ambler G, Cope TM, et al. The effect of neoadjuvant chemotherapy on physical fitness and survival in patients undergoing oesophagogastric cancer surgery. Eur J Surg Oncol. 2014;40:1313\u201320.","journal-title":"Eur J Surg Oncol"},{"key":"1404_CR22","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1200\/JCO.2010.33.0597","volume":"29","author":"M Ychou","year":"2011","unstructured":"Ychou M, Boige V, Pignon JP, Conroy T, Bouch\u00e9 O, Lebreton G, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29:1715\u201321.","journal-title":"J Clin Oncol"},{"key":"1404_CR23","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/bjs.9632","volume":"101","author":"HS Ahn","year":"2014","unstructured":"Ahn HS, Jeong SH, Son YG, Lee HJ, Im SA, Bang YJ, et al. Effect of neoadjuvant chemotherapy on postoperative morbidity and mortality in patients with locally advanced gastric cancer. Br J Surg. 2014;101:1560\u20135.","journal-title":"Br J Surg"},{"key":"1404_CR24","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/1477-7819-9-110","volume":"9","author":"Z-Y Li","year":"2011","unstructured":"Li Z-Y, Shan F, Zhang L-H, Bu Z-D, Wu A-W, Wu X-J, et al. Complications after radical gastrectomy following FOLFOX7 neoadjuvant chemotherapy for gastric cancer. World J Surg Oncol. 2011;9:110.","journal-title":"World J Surg Oncol"},{"key":"1404_CR25","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649\u201355.","journal-title":"Am J Clin Oncol"},{"key":"1404_CR26","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1002\/1097-0142(194811)1:4<634::AID-CNCR2820010410>3.0.CO;2-L","volume":"1","author":"DA Karnofsky","year":"1948","unstructured":"Karnofsky DA, Abelmann WH, Craver LF, Burchenal JH. The use of the nitrogen mustards in the palliative treatment of carcinoma. With particular reference to bronchogenic carcinoma. Cancer. 1948;1:634\u201356.","journal-title":"Cancer"},{"key":"1404_CR27","doi-asserted-by":"publisher","first-page":"83","DOI":"10.21037\/apm.2016.03.02","volume":"5","author":"R Chow","year":"2016","unstructured":"Chow R, Chiu N, Bruera E, Krishnan M, Chiu L, Lam H, et al. Inter-rater reliability in performance status assessment among health care professionals: a systematic review. Ann Palliat Med. 2016;5:83\u201392.","journal-title":"Ann Palliat Med"},{"key":"1404_CR28","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1002\/jso.24004","volume":"112","author":"H Nienhueser","year":"2015","unstructured":"Nienhueser H, Kunzmann R, Sisic L, Blank S, Strowitzk MJ, Bruckner T, et al. Surgery of gastric cancer and esophageal cancer: Does age matter? J Surg Oncol. 2015;112:387\u201395.","journal-title":"J Surg Oncol"},{"key":"1404_CR29","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1016\/j.ejso.2022.03.003","volume":"48","author":"WPM Dijksterhuis","year":"2022","unstructured":"Dijksterhuis WPM, Kroese TE, Verhoeven RHA, van Rossum PSN, Mook S, Haj Mohammad N, et al. A population-based study on treatment and outcomes in patients with gastric adenocarcinoma diagnosed with distant interval metastases. Eur J Surg Oncol. 2022;48:1964\u201371.","journal-title":"Eur J Surg Oncol"}],"container-title":["Gastric Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-023-01404-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10120-023-01404-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-023-01404-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T15:08:21Z","timestamp":1689952101000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10120-023-01404-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,7]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["1404"],"URL":"https:\/\/doi.org\/10.1007\/s10120-023-01404-2","relation":{},"ISSN":["1436-3291","1436-3305"],"issn-type":[{"value":"1436-3291","type":"print"},{"value":"1436-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,7]]},"assertion":[{"value":"27 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Prof. Dr. van Laarhoven reported being honorary chair upper GI faculty of European Society for Medical Oncology; serving in a consulting or advisory role for Amphera, Astellas, AstraZeneca, Beigene, BMS, Daiichy-Sankyo, Dragonfly, MSD, Novartis, and Servier; receiving research grants and nonfinancial support from Bayer, BMS, Celgene, Janssen, Incyte, Philips, Roche, and Servier; serving as speaker for Astellas, Benecke, Daiichy-Sankyo, JAAP, Medtalks, Novartis, and Travel Congress Management B.V. outside the submitted work. Dr. Verhoeven reported serving in a consulting or advisory role for Daiichi Sankyo; receiving research grant from Bristol Myers Squibb outside the submitted work. Prof. Dr. van Berge Henegouwen reported serving in a consulting or advisory role for Alesi Surgical, BBraun, Johnson and Johnson, Medtronic, and Viatris; receiving research grants from Stryker outside the submitted work. The remaining authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}